The verified answer
As of Sep 2026, DEPLOY verifies Edwards Lifesciences: 1 model, 3 deployments across 3 regions, 1 active incident. 1 source back the record.
CategorySurgical robots
Overview
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California , specializing in tissue heart valves and transcatheter technologies for structural heart disease. Founded by Miles Lowell Edwards in 1958, the company invented the first successful artificial heart valve (the Starr-Edwards valve) and pioneered transcatheter aortic valve replacement (TAVR) with its SAPIEN 3 platform. The company is listed on the NYSE (EW) and is an S&P 500 component.
Verified record
- Verified deployments
- 3 deployments on file
- Active incidents
- 1 incident on file
Key facts
Previous CEO
Founder
NYSE Ticker
S&P 500 Component
Key Product
Manufacturingsee manufacturing →
Parent Company History
Revenue 2025
Employees
Data & sources
Web sources
1
1 source backing this record.View all →
Models (1)
View all models →Partnerships
Every company Edwards Lifesciences has built with, alongside the ones only announced in a press release.
Edwards Lifesciences on the deployment map
View the global map3 verified deployments across 3 regions, newest verified Jan 2019. Explore where Edwards Lifesciences's robots are operating, by place and type.
- operationalSAPIEN 3 Transcatheter Heart Valve at Los Angeles, California, USA →West Coast · verified Jan 2019
- operationalSAPIEN 3 Transcatheter Heart Valve at Cleveland, Ohio, USA →Midwest · verified Apr 2017
- operationalSAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada →North America · verified Jan 2013
View the full Edwards Lifesciences deployment record →
Relationships
Current leadership (3)
- Bernard J. Zovighian CEOreported, not verified
- Michael Mussallem Former Chairman & CEOreported, not verified
- Miles Lowell Edwards Founderreported, not verified
Founders (1)
- Miles Lowell Edwardscofounderno longer at company
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Edwards Lifesciences (1)
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Operator customers (1)
- Edwards Lifesciences3 deployments
Recent coverage
Edwards Lifesciences in third-party press
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Financial state
- Employees
- 16,000as of 2025-12-31(reported)
- Reporting basis
- sec_10k
- Lifecycle stage
- mature
- Counterparty risk class
- low
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Partnerships
4 total · 4 operating
Every company Edwards Lifesciences has built with, alongside the ones only announced in a press release.
Most recent
All 4 partnerships
open in the atlas →- technology—operating
- technology—operating
- technology—operating
- technology—operating
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJun 8, 2026
Added to the verified registry
- Incident recordedMay 16, 2025
FDA Class I recall of Edwards Lifesciences arterial cannulae due to risk of wire exposure
- Deployment verifiedVerifiedJan 1, 2019
SAPIEN 3 Transcatheter Heart Valve at Los Angeles, California, USA
- Deployment verifiedVerifiedApr 1, 2017
SAPIEN 3 Transcatheter Heart Valve at Cleveland, Ohio, USA
- Deployment verifiedVerifiedJan 1, 2013
SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada
Sources (1)
Common questions
What is Edwards Lifesciences?
What does Edwards Lifesciences make?
Is Edwards Lifesciences publicly traded?
Who competes with Edwards Lifesciences?
Who is the CEO of Edwards Lifesciences?
How can I invest in Edwards Lifesciences?
Where is Edwards Lifesciences headquartered?
Who owns Edwards Lifesciences?
Where does Edwards Lifesciences operate robots?
How many robots has Edwards Lifesciences deployed?
Is Edwards Lifesciences a top robotics company?
Are there any incidents involving Edwards Lifesciences?
Is Edwards Lifesciences safe?
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-21
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-08-21
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Edwards Lifesciences.Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
In the press
Recent coverage mentioning Edwards Lifesciences from third-party publications. Automatically surfaced; not part of the verified registry record.
A continuous monitoring medtech vet charts the course to a less-invasive future
Becton, Dickinson and Co. (BD) Worldwide President of Advanced Patient Monitoring Tim Patz spearheaded BD’s launch of its new HemoSphere Stream Module, a noninvasive monitoring…
CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences
CMS’s proposed expansion of Medicare TAVR coverage to include select asymptomatic severe aortic stenosis patients and reduce access barriers for symptomatic patients could…
FTC Challenges Anticompetitive Medical Device Deal
The FTC challenged Edwards Lifesciences' acquisition of JenaValve, alleging it would disrupt competition for revolutionary heart condition devices.
FDA: Edwards Lifesciences Removes Arterial Cannula due to Risk of Wire Exposure
FDA issued a Class I recall for Edwards Lifesciences OptiSite Arterial Perfusion Cannula and Peripheral Femoral Arterial Cannula models due to risk of wire exposure that could…
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences reported Q4 and full-year 2025 financial results, with revenue of US.07 billion.
Edwards Lifesciences chair Michael Mussallem retires from board
Michael Mussallem retired from the Edwards Lifesciences board after 23 years as CEO and chair, having led the company since its 2000 IPO spin-off from Baxter.
Machine-readable surfaces
- Markdown mirror: /companies/edwards-lifesciences.md
- RSS feed: /companies/edwards-lifesciences/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/311e9cc4-68db-4d74-b74c-33fd30682fc4
- Revision history: /companies/edwards-lifesciences/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Video
How the EVOQUE valve is implanted via the transfemoral approach: A step-by-step illustration of tricuspid valve replacement with the EVOQUE Tricuspid Valve Replacement System. Content related to Edwards Lifesciences de
In 1958, Miles “Lowell” Edwards set out to build an artificial heart. But like so many other great inventors, Edwards and his trusted partner, Dr. Albert Starr,
Cutting-edge medical science helped Edwards Lifesciences' stock stay healthy so far in 2017, with a rise of over 25% year to date. Could it continue to head hig
Edwards Lifesciences CEO Michael Mussallem tells CNBC's Jim Cramer that the medical equipment company has prioritized improving care for structural heart diseas
Discover the challenges and requirements for the effective treatment of tricuspid valve disease. A global panel of experts draws upon multi-centre, real-world e
Driven by a passion to help, Edwards Lifesciences collaborates with the world’s leading clinicians and researchers, working to improve outcomes and enhance live
There are many different pathways students can take to be involved in medical innovation and entrepreneurship. Hear from a variety of industry professionals as
In this episode, Gary speaks with Michael A. Mussallem, Chairman and CEO, Edwards Lifesciences. They spoke about the future of healthcare technology and innovat
Rick, a farmer from Canada, has been hardworking his entire life. As a child, he was sick with rheumatic fever, which left his heart valves damaged and caused h
Heat Index
Serious58/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
Edwards Lifesciences draws attention at the 49th percentile but verifies reality at the 57th percentile among surgical robots. Hype Gap -7.6, 27th widest among surgical robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Limited public funding data for capital position assessment.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Sep 6, 2026